{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:08:23Z","timestamp":1753891703447,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00510","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T08:13:00Z","timestamp":1586938380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Tejas","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Dimou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Doebele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Ferrigno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/nejmoa1612674","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s1470-2045(11)70393-x","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"B8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0032-1329535","article-title":"Management of colonic volvulus","volume":"25","author":"Gingold","year":"2012","journal-title":"Clin Colon Rectal Surg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/0002-9610(73)90163-3","article-title":"Volvulus of the cecum and ascending colon","volume":"125","author":"Grover","year":"1973","journal-title":"Am J Surg."},{"key":"B10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/fon-2016-0431","article-title":"Malignant bowel obstruction in advanced ovarian cancer","volume":"13","author":"Dean","year":"2017","journal-title":"Future Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JOP.2017.022210","article-title":"Management of malignant bowel obstruction associated with GI cancers","volume":"13","author":"Franke","year":"2017","journal-title":"J Oncol Pract."},{"key":"B12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/gastro\/got026","article-title":"Low-grade appendiceal neoplasm presenting as a volvulus of the cecum","volume":"1","author":"Costa","year":"2013","journal-title":"Gastroenterol Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00595-008-3913-5","article-title":"Intestinal malrotation associated with colon cancer in an adult: report of a case","volume":"39","author":"Ren","year":"2009","journal-title":"Surg Today."},{"key":"B14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/00000658-197506000-00021","article-title":"Volvulus of the cecum","volume":"181","author":"Andersson","year":"1975","journal-title":"Ann Surg."},{"key":"B15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S2213-2600(17)30378-8","article-title":"Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study","volume":"5","author":"Ahn","year":"2017","journal-title":"Lancet Respir Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10637-018-0581-1","article-title":"Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer","volume":"36","author":"Tamiya","year":"2018","journal-title":"Invest N Drugs."},{"key":"B17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2016.06.012","article-title":"Gastrointestinal perforations in patients treated with erlotinib: a report of two cases with fatal outcome and literature review","volume":"99","author":"Gass-J\u00e9gu","year":"2016","journal-title":"Lung Cancer."},{"key":"B18","first-page":"34","article-title":"Duodenal perforation secondary to erlotinib therapy in a patient with non-small cell lung cancer","volume":"116","author":"Rafiullah","year":"2017","journal-title":"WMJ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1083\/jcb.200701086","article-title":"c-Met is essential for wound healing in the skin","volume":"177","author":"Chmielowiec","year":"2007","journal-title":"J Cell Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.canlet.2016.07.021","article-title":"Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment","volume":"380","author":"Shi","year":"2016","journal-title":"Cancer Lett"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.jtho.2017.02.020","article-title":"Tolerable and effective combination of full-dose crizotinib and osimertinib targeting MET amplification sequentially emerging after T790M positivity in EGFR-mutant non-small cell lung cancer","volume":"12","author":"York","year":"2017","journal-title":"J Thorac Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00510\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T08:13:02Z","timestamp":1586938382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00510\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":21,"alternative-id":["10.3389\/fonc.2020.00510"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00510","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"article-number":"510"}}